The role of insulin and IGF system in pancreatic cancer

Journal of Molecular Endocrinology

Volumn 50, Issue 3, 2013, Pages

  Trajkovic Arsic, Marija ^a   Kalideris, Evdokia ^a   Siveke, Jens T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Insulin; Insulin like growth factor; Pancreatic cancer

Indexed keywords

GLUCOSE; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ACINAR CELL CARCINOMA; CANCER RISK; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; GLUCOSE METABOLISM; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; PANCREATIC NEOPLASMS; RECEPTOR, INSULIN; SOMATOMEDINS;

EID: 84876744389     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0259     Document Type: Review

References (78)

1. Aggarwal G, Rabe KG, Petersen GM & Chari ST 2012 New-onset diabetes in pancreatic cancer: a study in the primary care setting. Pancreatology 12 156-161. (doi:10.1016/j.pan.2012.02.003)
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N & Perucho M 1988 Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53 549-554. (doi:10.1016/0092-8674(88)90571-5)
3. Amgen 2012 Amgen announces termination of ganitumab phase 3 study for futility. In Metastatic Pancreatic Cancer.
4. Appleman VA, Ahronian LG, Cai J, Klimstra DS & Lewis BC 2012 KRAS (G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Molecular Cancer Research 10 1228-1239. (doi:10.1158/1541-7786.MCR-12-0340-T)
5. Ardito CM, Gruner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC et al. 2012 EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22 304-317. (doi:10.1016/j.ccr.2012.07.024)
6. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL & Reddy SA 2005 Insulin receptor substrate is amediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Research 65 9164-9168. (doi:10.1158/0008-5472.CAN-05-0779)
7. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, Ahmad A & Sarkar FH 2011 The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochimica et Biophysica Acta 1815 135-146. (doi:10.1016/j.bbcan.2010.11.003)
8. Barbieri M, Bonafe M, Franceschi C & Paolisso G 2003 Insulin/IGF-Isignaling pathway: an evolutionarily conserved mechanism of longevity from yeast to humans. American Journal of Physiology. Endocrinology and Metabolism 285 E1064-E1071.
9. Bardeesy N & DePinho RA 2002 Pancreatic cancer biology and genetics. Nature Reviews. Cancer 2 897-909. (doi:10.1038/nrc949)
10. Barreto SG, Carati CJ, Toouli J & Saccone GT 2010 The islet-acinar axis of the pancreas: more than just insulin. American Journal of Physiology. Gastrointestinal and Liver Physiology 299 G10-G22. (doi:10.1152/ajpgi.00077.2010)
11. Belfiore A, Frasca F, Pandini G, Sciacca L & Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 30 586-623. (doi:10.1210/er.2008-0047)
12. Ben Q, Cai Q, Li Z, Yuan Y, Ning X, Deng S & Wang K 2011 The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. European Journal of Cancer 47 248-254. (doi:10.1016/ j.ejca.2010.07.010)
13. Bergmann U, Funatomi H, Yokoyama M, Beger HG & Korc M 1995 Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Research 55 2007-2011.
14. Bergmann U, Funatomi H, Kornmann M, Beger HG & Korc M 1996 Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochemical and Biophysical Research Communications 220 886-890. (doi:10.1006/bbrc.1996.0500)
15. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S & Butler PC 2010 Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 53 21-26. (doi:10.1007/s00125-009-1556-8)
16. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH & Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566. (doi:10.1126/science.279.5350.563)
17. Cui Y & Andersen DK 2012 Diabetes and pancreatic cancer. Endocrine-Related Cancer 19 F9-F26. (doi:10.1530/ERC-12-0105)
18. DeChiara TM, Efstratiadis A & Robertson EJ 1990 A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345 78-80. (doi:10.1038/345078a0)
19. De Meyts P 2004 Insulin and its receptor: structure, function and evolution. BioEssays 26 1351-1362. (doi:10.1002/bies.20151)
20. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL & Li D 2010 Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 139 464-473 (473 e461-463). (doi:10.1053/j.gastro.2010.04.042)
21. Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL & Li D 2012 Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiology 36 206-211. (doi:10.1016/j.canep.2011.05.013)
22. Emerman JT, Leahy M, Gout PW & Bruchovsky N 1985 Elevated growth hormone levels in sera from breast cancer patients. Hormone and Metabolic Research 17 421-424. (doi:10.1055/s-2007-1013563)
23. Fisher WE, Boros LG & Schirmer WJ 1996 Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. Journal of Surgical Research 63 310-313. (doi:10.1006/jsre.1996.0266)
24. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A & Vigneri R 1999 Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology 19 3278-3288.
25. Gallagher EJ & LeRoith D 2011 Minireview: IGF, insulin, and cancer. Endocrinology 152 2546-2551. (doi:10.1210/en.2011-0231)
26. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L & Dyer A 2000 Abnormal glucose metabolism and pancreatic cancer mortality. Journal of the American Medical Association 283 2552-2558. (doi:10.1001/jama.283.19.2552)
27. Garofalo RS 2002 Genetic analysis of insulin signaling in Drosophila. Trends in Endocrinology and Metabolism 13 156-162. (doi:10.1016/S1043-2760(01)00548-3)
28. Godsland IF 2010 Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clinical Science 118 315-332. (doi:10.1042/CS20090399)
29. Grouven U, Hemkens LG, Bender R & Sawicki PT 2010 Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter]. Diabetologia 53 209-211. (doi:10.1007/s00125-009-1582-6)
30. Hakam A, Fang Q, Karl R & Coppola D 2003 Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Digestive Diseases and Sciences 48 1972-1978. (doi:10.1023/A:1026122421369)
31. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE & Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393-1396. (doi:10.1016/S0140-6736(97)10384-1)
32. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N & Depinho RA 2006 Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development 20 1218-1249. (doi:10.1101/gad.1415606)
33. Hidalgo M 2010 Pancreatic cancer. New England Journal of Medicine 362 1605-1617. (doi:10.1056/NEJMra0901557)
34. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA et al. 2003 Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4 437-450. (doi:10.1016/S1535-6108(03)00309-X)
35. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S & Tuveson DA 2005 Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 469-483. (doi:10.1016/j.ccr.2005.04.023)
36. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM, Deng CX, Hruban RH, Adsay NV, Tuveson DA et al. 2007 Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11 229-243. (doi:10.1016/j.ccr.2007.01.017)
37. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics, 2008. CA: A Cancer Journal for Clinicians 58 71-96. (doi:10.3322/CA.2007.0010)
38. Karna E, Surazynski A, Orlowski K, Laszkiewicz J, Puchalski Z, Nawrat P & Palka J 2002 Serum and tissue level of insulin-like growth factor-I (IGF-I) and IGF-I binding proteins as an index of pancreatitis and pancreatic cancer. International Journal of Experimental Pathology 83 239-245. (doi:10.1046/j.1365-2613.2002.00237.x)
39. Korc M 1998 Role of growth factors in pancreatic cancer. Surgical Oncology Clinics of North America 7 25-41.
40. Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, White MF & Korc M 1998 Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Research 58 4250-4254.
41. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA & Kahn CR 1999 Tissue-specific knockout of the insulin receptor in pancreatic b cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 329-339. (doi:10.1016/S0092-8674(00)80546-2)
42. Lankisch PG, Manthey G, Otto J, Koop H, Talaulicar M, Willms B & Creutzfeldt W 1982 Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion 25 211-216. (doi:10.1159/000198833)
43. Li D, Xie K, Wolff R & Abbruzzese JL 2004 Pancreatic cancer. Lancet 363 1049-1057. (doi:10.1016/S0140-6736(04)15841-8)
44. Li D, Yeung SC, Hassan MM, Konopleva M & Abbruzzese JL 2009 Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137 482-488. (doi:10.1053/j.gastro.2009.04.013)
45. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM & Hochwald SN 2008 FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29 1096-1107. (doi:10.1093/carcin/bgn026)
46. Malaguarnera R & Belfiore A 2011 The insulin receptor: a new target for cancer therapy. Frontiers in Endocrinology 2 93. (doi:10.3389/fendo.2011.00093)
47. Massoner P, Ladurner-Rennau M, Eder IE & Klocker H 2010 Insulin-like growth factors and insulin control a multifunctional signaling network of significant importance in cancer. British Journal of Cancer 103 1479-1484. (doi:10.1038/sj.bjc.6605932)
48. Mazur PK & Siveke JT 2012 Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 61 1488-1500. (doi:10.1136/gutjnl-2011-300756)
49. McCarty MF 2001 Insulin secretion as a determinant of pancreatic cancer risk. Medical Hypotheses 57 146-150. (doi:10.1054/mehy.2001.1316)
50. Mossner J, Logsdon CD, Goldfine ID & Williams JA 1984 Regulation of pancreatic acinar cell insulin receptors by insulin. American Journal of Physiology 247 G155-G160.
51. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C & Barbacid M 2012 EGF receptor signaling is essential for k-ras oncogenedriven pancreatic ductal adenocarcinoma. Cancer Cell 22 318-330. (doi:10.1016/j.ccr.2012.08.001)
52. Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A & Raymond E 2012 Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer and Metastasis Reviews.
53. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO & Svensson J 2009 The role of liver-derived insulin-like growth factor-I. Endocrine Reviews 30 494-535. (doi:10.1210/er.2009-0010)
54. Okabayashi Y, Maddux BA, McDonald AR, Logsdon CD, Williams JA & Goldfine ID 1989 Mechanisms of insulin-induced insulin-receptor downregulation. Decrease of receptor biosynthesis and mRNA levels. Diabetes 38 182-187. (doi:10.2337/diabetes.38.2.182)
55. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID & Belfiore A 1999 Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanismof IGF-I signaling. Clinical Cancer Research 5 1935-1944.
56. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R & Belfiore A 2002 Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. Journal of Biological Chemistry 277 39684-39695. (doi:10.1074/jbc.M202766200)
57. Pollak M 2008a Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 8 915-928. (doi:10.1038/nrc2536)
58. Pollak M 2008b Insulin, insulin-like growth factors and neoplasia. Best Practice & Research. Clinical Endocrinology & Metabolism 22 625-638. (doi:10.1016/j.beem.2008.08.004)
59. Reaven GM 1995 Pathophysiology of insulin resistance in human disease. Physiological Reviews 75 473-486.
60. Rieder S, Michalski CW, Friess H & Kleeff J 2011 Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anti-Cancer Agents in Medicinal Chemistry 11 427-433. (doi:10.2174/187152011795677454)
61. Rozengurt E, Sinnett-Smith J & Kisfalvi K 2010 Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clinical Cancer Research 16 2505-2511. (doi:10.1158/1078-0432.CCR-09-2229)
62. Samani AA, Yakar S, LeRoith D & Brodt P 2007 The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocrine Reviews 28 20-47. (doi:10.1210/er.2006-0001)
63. Siddle K 2011 Signalling by insulin and IGF receptors: supporting acts and new players. Journal of Molecular Endocrinology 47 R1-R10. (doi:10.1530/JME-11-0022)
64. Siveke JT & Schmid RM 2005 Chromosomal instability in mousemetastatic pancreatic cancer - it's Kras and Tp53 after all. Cancer Cell 7 405-407. (doi:10.1016/j.ccr.2005.04.025)
65. Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH & Testa JR 2001 AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Research 61 589-593.
66. Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M & Yoshida T 2010 Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World Journal of Gastroenterology 16 1854-1858. (doi:10.3748/wjg.v16.i15.1854)
67. Ueda S, Hatsuse K, Tsuda H, Ogata S, Kawarabayashi N, Takigawa T, Einama T, Morita D, Fukatsu K, Sugiura Y et al. 2006 Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Modern Pathology 19 788-796.
68. Ulanet DB, Ludwig DL, Kahn CR & Hanahan D 2010 Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. PNAS 107 10791-10798. (doi:10.1073/pnas.0914076107)
69. Valsecchi ME, McDonald M, Brody JR, Hyslop T, Freydin B, Yeo CJ, Solomides C, Peiper SC & Witkiewicz AK 2012 Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer 118 3484-3493. (doi:10.1002/cncr.26661)
70. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, Vigneri R & Belfiore A 2001 The IGF system in thyroid cancer: new concepts. Molecular Pathology 54 121-124. (doi:10.1136/mp.54.3.121)
71. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Reviews. Cancer 2 489-501. (doi:10.1038/nrc839)
72. Weroha SJ & Haluska P 2008 IGF-1 receptor inhibitors in clinical trials - early lessons. Journal of Mammary Gland Biology and Neoplasia 13 471-483. (doi:10.1007/s10911-008-9104-6)
73. Williams JA & Goldfine ID 1985 The insulin-pancreatic acinar axis. Diabetes 34 980-986. (doi:10.2337/diabetes.34.10.980)
74. Yakar S & Adamo ML 2012 Insulin-like growth factor 1 physiology: lessons from mouse models. Endocrinology and Metabolism Clinics of North America 41 231-247. (doi:10.1016/j.ecl.2012.04.008)
75. Yakar S, Pennisi P, Zhao H, Zhang Y & LeRoith D 2004 Circulating IGF-1 and its role in cancer: lessons from the IGF-1 gene deletion (LID) mouse. Novartis Foundation Symposium 262 3-9 (Discussion 9-18, 265-268).
76. Yao Z, Okabayashi Y, Yutsudo Y, Kitamura T, Ogawa W & Kasuga M 2002 Role of Akt in growth and survival of PANC-1 pancreatic cancer cells. Pancreas 24 42-46. (doi:10.1097/00006676-200201000-00006)
77. Yee D 2012 Insulin-like growth factor receptor inhibitors: baby or the bathwater? Journal of the National Cancer Institute 104 975-981. (doi:10.1093/jnci/djs258)
78. Yu H & Rohan T 2000 Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489. (doi:10.1093/jnci/92.18.1472)